Derya Tilki1, Felix Preisser2, Markus Graefen2, Hartwig Huland2, Raisa S Pompe3. 1. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. Electronic address: d.tilki@uke.de. 2. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 3. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Abstract
The impact of biochemical recurrence (BCR) after radical treatment of prostate cancer on oncological outcomes remains unclear. A new European Association of Urology BCR risk stratification (low and high risk) has been proposed. To validate these risk groups, we retrospectively analyzed data for 1125 post-radical prostatectomy (RP) BCR patients (surgery between 1992 and 2006). Univariable Kaplan-Meier plots and multivariable Cox regression models with time-dependent covariates were used to test the independent predictor status of the risk grouping on metastatic progression (MP) and prostate cancer-specific mortality (PCSM). The 5-yr MP-free and PCSM-free survival rates were significantly higher among patients with low BCR risk compared to their high-risk counterparts. In multivariable analyses, the BCR risk grouping reached independent predictor status for MP (hazard ratio [HR] 3.46; p<0.001) and PCSM (HR 5.12; p<0.001). Salvage radiation therapy, especially when delivered at prostate-specific antigen <0.5ng/ml, was highly protective. Our findings corroborate the validity of this novel BCR risk grouping, which is easily applicable in daily practice and could be valuable in decision-making for salvage therapy and clinical trials. PATIENT SUMMARY: The European Association of Urology grouping for the risk of biochemical recurrence of prostate cancer after radical prostatectomy was valid when applied in a European study cohort.
The impact of biochemical recurrence (BCR) after radical treatment of prostate cancer on oncological outcomes remains unclear. A new European Association of Urology BCR risk stratification (low and high risk) has been proposed. To validate these risk groups, we retrospectively analyzed data for 1125 post-radical prostatectomy (RP) BCR patients (surgery between 1992 and 2006). Univariable Kaplan-Meier plots and multivariable Cox regression models with time-dependent covariates were used to test the independent predictor status of the risk grouping on metastatic progression (MP) and prostate cancer-specific mortality (PCSM). The 5-yr MP-free and PCSM-free survival rates were significantly higher among patients with low BCR risk compared to their high-risk counterparts. In multivariable analyses, the BCR risk grouping reached independent predictor status for MP (hazard ratio [HR] 3.46; p<0.001) and PCSM (HR 5.12; p<0.001). Salvage radiation therapy, especially when delivered at prostate-specific antigen <0.5ng/ml, was highly protective. Our findings corroborate the validity of this novel BCR risk grouping, which is easily applicable in daily practice and could be valuable in decision-making for salvage therapy and clinical trials. PATIENT SUMMARY: The European Association of Urology grouping for the risk of biochemical recurrence of prostate cancer after radical prostatectomy was valid when applied in a European study cohort.
Authors: Michael A Gorin; Steven P Rowe; Mark C Markowski; Ramy Sedhom; Wei Fu; Javaughn Corey R Gray; Mario A Eisenberger; Martin G Pomper; Kenneth J Pienta Journal: J Urol Date: 2020-04-06 Impact factor: 7.450
Authors: Justin Ferdinandus; Wolfgang P Fendler; Andrea Farolfi; Samuel Washington; Osama Mohamad; Miguel H Pampaloni; Peter J H Scott; Melissa Rodnick; Benjamin L Viglianti; Matthias Eiber; Ken Herrmann; Johannes Czernin; Wesley R Armstrong; Jeremie Calais; Thomas A Hope; Morand Piert Journal: J Nucl Med Date: 2021-10-07 Impact factor: 11.082
Authors: Liang Dong; Yun Su; Yinjie Zhu; Mark C Markowski; Mei Xin; Michael A Gorin; Baijun Dong; Jiahua Pan; Martin G Pomper; Jianjun Liu; Kenneth J Pienta; Wei Xue; Steven P Rowe Journal: J Nucl Med Date: 2021-07-29 Impact factor: 10.057